Clinical trial
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
NCT00325650 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00325650 |
|---|---|
| Title | Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Long-term Administration of Rimonabant in the Prevention of Type 2 Diabetes in Patients With Prediabetic Status (i.e., Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance… |
| Acronym | RAPSODI |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prediabetic State |
| Intervention type | Drug |
| Interventions | Rimonabant, Placebo (for Rimonabant) |
| Enrollment | 2,420 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | May 15, 2006 |
| Last update posted | May 18, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: